The demand for new drug
candidates for antimicrobial resistant infections is increasing. Antimicrobial
resistance is a serious concern to global public health as it resulted in long
duration of illness, the requirement of additional tests and use of more expensive
drugs. Antimicrobial resistance occurs when microorganisms such as bacteria,
viruses, parasites and fungi change and adapted to drugs when they are exposed
to antimicrobial drugs such as antibiotics, antivirals, antifungals, anthelmintic
and others. According to World Health Organization (WHO), globally 4,80,000
people are developing multi-drug resistant TB each year and drug resistance is
starting to complicate the treatment of malaria and HIV as well. Companies are investing in developing the new
drug candidates to treat drug-resistant infections.
THE BUSINESS RESEARCH COMPANY EXPECTS
THE GLOBAL ANTI-INFECTIVE DRUGS MARKET TO GROW TO $134 BILLION BY 2021
North America was the largest
region in the anti-infective drugs market in 2017, accounting for almost
one-third of the market share. This can be attributed to the presence of
established health care networks and high healthcare spending in the region.
Order the report at https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report-2018
According to The Business Research
Company’s Consultant, Nitin Gianchandani, companies in this market are active
with multiple strategic collaborations and agreements. Top companies in the
anti-infective drug market are strategically partnering and collaborating with
other companies to broaden their products and services. For instance, in May
2015, Janssen Pharmaceuticals, Inc., subsidiary of Johnson & Johnson has
entered into an exclusive worldwide license and collaboration arrangement with
Achillion Pharmaceuticals, Inc. to develop and commercialize one or more of
Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102,
ACH-3422 and sovaprevir. Also, in December 2016, Evotec AG was in a strategic
alliance with Forge Therapeutics, Inc. to advance its novel Gram-negative
antibiotic programme targeting 'LpxC' for the treatment of bacterial
infections. Chimerix and ContraVir
Pharmaceuticals also entered into a strategic collaboration for antiviral drug
candidate CMX157.
Download a sample of the report at:
Gilead Sciences, Inc. was the
largest company in the anti-infective drugs market in 2017, with revenues of
$16.2 billion in 2016. Gilead’s growth strategy aims to focus on development of
products for HIV, viral hepatitis and other diseases through collaborations
with other companies, medical research institutions and universities. In 2016,
the company partnered with more than 2,000 organizations for the clinical
development of certain products and support for research programs. Gilead made
a total funding of about $460 million to support the collaborations.
Infectious
diseases are disorders caused by several pathogenic organisms such as bacteria,
viruses, fungi or parasites. These diseases can be transmitted or spread from
one person to another through direct contact or indirect contact.
Anti-infective drugs are used to treat or prevent these infectious diseases by
inhibiting the spread of an infectious agent (static) or by killing the
infectious agent (cidal). The market numbers within this briefing are
restricted to pharmaceutical (drug) treatments and do not cover biologic
treatments for these conditions which are included in a separate briefing.
Anti-infective Drugs Global Market
Report 2018 is a
detailed report giving a unique insight into this market. The report is priced
at $4000 for an individual user. To use across your office, the price is $6000 and
$8000 if you wish to use across a multinational company.
About
The Business Research Company:
Visit TheBusinessResearchCompany.com,
mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for
more information on this and many other titles.
The Business Research Company is a
market research and intelligence company, which excels in company, market and
consumer research.
It has research professionals at its
offices in the UK, India and the US as well a network of trained researchers
globally. It has specialist consultants in a wide range of industries including
manufacturing, healthcare, chemicals and technology.
The Business Research Company's
management has more than 20 years of varied business research experience. They
have delivered hundreds of research projects to the senior management of some
of the world's largest organizations.
Contact Information:
The
Business Research Company
Europe:
+44 207 1930 708
Asia:
+91 8897263534
Americas:
+1 315 623 0293
Email: info@tbrc.info
No comments:
Post a Comment